Vera Therapeutics

Historical price data

Vera Therapeutics is a clinical-stage biotech focused on developing transformative treatments for B-cell and plasma cell-driven autoimmune diseases. Its core achievement is the successful Phase 3 ORIGIN 3 trial of atacicept in IgA nephropathy (IgAN), meeting its primary endpoint in June 2025, which sets the stage for a potential first-in-class therapy. The company's strategy leverages a deep understanding of B-cell biology to selectively target pathogenic drivers, with a lean operational model aimed at efficiently advancing its pipeline toward commercialization and addressing high unmet medical needs.

Platform centered on selective modulation of B-cell and plasma cell biology through targeted inhibition of key survival cytokines BAFF and APRIL, using fusion protein and monoclonal antibody modalities.

Atacicept faces competition in IgAN from SGLT2 inhibitors, endothelin receptor antagonists, and complement inhibitors. Its dual BAFF/APRIL inhibition and subcutaneous administration differentiate it from BAFF-only inhibitors and IV-infused therapies. The lupus nephritis landscape is more crowded with established treatments.